Mangoceuticals vs Sera Prognostics
Mangoceuticals reported revenue of $0 million in fiscal 2025, 5.0 times Sera Prognostics' $0 million in fiscal 2025. Mangoceuticals' revenue fell 26.0% in its latest year, and Sera Prognostics' grew 5.2%. Mangoceuticals had an operating margin of -3954.3%, against -45066.7% at Sera Prognostics.
Side by side
| Mangoceuticals | Sera Prognostics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $0M |
| Revenue growth | −26.0% | 5.2% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 54.9% | −102.5% |
| Operating margin | −3,954.3% | −45,066.7% |
| Net margin | −4,526.8% | −39,417.3% |
| Free cash flow | — | −$26M |
| Free cash flow margin | — | −32,529.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 408.9% | 43.8% |
| Last close | $0.13 | $1.89 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $514,580 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MangoceuticalsSera Prognostics
Operating margin
Percent of revenue
MangoceuticalsSera Prognostics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MangoceuticalsSera Prognostics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Mangoceuticals and Sera Prognostics pages.